506 Carnegie Center Drive, Suite 400
119 articles with Sandoz
NDMA is classified as a probable human carcinogen
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
To date, Sandoz has not received any reports of adverse events related to use of the product as part of this recall.
Sandoz Inc. voluntarily recalls Losartan Potassium and Ezetimibe in prescription drug bottles in the U.S. due to failure to meet child-resistant closure requirements
Sandoz Inc. today announced a voluntary recall and corrective action notice for particular lots of product distributed in the U.S. in prescription drug bottles because the cap and bottle combination does not meet federal standards for child-resistant packaging, posing a risk of harm if the tablets are swallowed by children
Sandoz' biosimilar to Enbrel was approved in 2016 by the FDA but has remained off the market due to the patent protection surrounding Amgen's blockbuster rheumatoid arthritis treatment.
Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine
Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need
Sandoz announced its donation of over 4,000 packs of SYMJEPI™ 0.3 mg Injection for immediate use in free and charity clinics in the US through its collaboration with Americares.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014
EirGenix, Inc. announced that it has entered into a license agreement with global generic and biosimilar drug manufacturer Sandoz AG, granting an exclusive license to Sandoz for right of commercialization of EirGenix 's breast cancer biosimilar drug, EG12014 globally with the exception of Taiwan and mainland China.
4/26/2019Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
Maryland-based United Therapeutics said Sandoz has had eight years to ensure it had its own delivery system in place for its generic pulmonary arterial hypertension medication.
United Therapeutics Corporation was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc.
Sandoz, a Novartis division and a global leader in biosimilars, today announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and Drug Administration (FDA) to address an FDA complete response letter received in June 2016.
Sandoz exclusively launches treprostinil injection, the first generic version of Remodulin®, in the US
Sandoz announced the US availability of Treprostinil Injection, the first fully substitutable AP rated generic version of Remodulin®* Injection, sold by United Therapeutics Corporation, including 180 days of marketing exclusivity for the product.
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
3/15/2019Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis
Sandoz Inc., a Novartis division, announced that the authorized generic of SUBOXONE® 1 Sublingual Film by Indivior Inc.
Sandoz Inc. (Sandoz), a Novartis division, announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.